Mechanism of action of interferon and ribavirin in treatment of hepatitis C

Jordan J. Feld and Jay H. Hoofnagle ()
Additional contact information
Jordan J. Feld: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases
Jay H. Hoofnagle: National Institutes of Health

Nature, 2005, vol. 436, issue 7053, 967-972

Abstract: Abstract Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, interferon-α (IFN-α) was a natural choice for treatment. Whereas treatment with IFN-α alone achieved only modest success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses. However, half of the infected individuals with chronic disease do not achieve sustained clearance of hepatitis C virus. To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential.

Date: 2005
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature04082 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:436:y:2005:i:7053:d:10.1038_nature04082

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature04082

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().